The conclusion that myeloperoxidase inhibition is not protective against anti-neutrophil cytoplasmic autoantibody –associated vasculitis is premature
Florez-Barros et al. assert that myeloperoxidase inhibitor (MPO-I) was not protective against anti-myeloperoxidase (MPO) vasculitis, as MPO-I failed to ameliorate kidney function, proteinuria, or pathologic findings in vivo.1 However, their observations are insufficient to assess its renal protective effect for 3 reasons.
Source: Kidney International - Category: Urology & Nephrology Authors: Tomoki Taniguchi, Ryosuke Hiwa, Akio Morinobu Tags: Letter to the Editor Source Type: research